Jamie Christensen - 17 Jan 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
EVP, Chief Scientific Officer
Signature
/s/ Reena Desai, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
-$95,142
Form type
4
Filing time
19 Jan 2023, 08:45:36 UTC
Previous filing
05 Jan 2023
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Sale $57,549 -1,358 -1.4% $42.38 98,765 17 Jan 2023 Direct F1
transaction MRTX Common Stock Sale $37,593 -887 -0.9% $42.38 97,878 17 Jan 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022.
F2 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.